Agenus (AGEN) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Agenus (NASDAQ:AGEN) issued its earnings results on Tuesday. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04), Fidelity Earnings reports. The company had revenue of $12.80 million during the quarter, compared to the consensus estimate of $10.76 million.
AGEN stock traded up $0.13 during trading on Wednesday, hitting $2.07. 2,337,152 shares of the company traded hands, compared to its average volume of 1,191,802. The stock has a market capitalization of $214.10 million, a PE ratio of -1.68 and a beta of 2.19. Agenus has a 1 year low of $1.54 and a 1 year high of $6.19.
Separately, Zacks Investment Research cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, July 23rd.
COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/07/agenus-agen-announces-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Recommended Story: What is a put option?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.